CZ165693A3 - 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds - Google Patents

5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds Download PDF

Info

Publication number
CZ165693A3
CZ165693A3 CS931656A CS165693A CZ165693A3 CZ 165693 A3 CZ165693 A3 CZ 165693A3 CS 931656 A CS931656 A CS 931656A CS 165693 A CS165693 A CS 165693A CZ 165693 A3 CZ165693 A3 CZ 165693A3
Authority
CZ
Czechia
Prior art keywords
group
compound
indol
formula
hydrogen
Prior art date
Application number
CS931656A
Other languages
Czech (cs)
English (en)
Inventor
Jolanta T Nowakowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CZ165693A3 publication Critical patent/CZ165693A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CS931656A 1991-02-12 1992-02-03 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds CZ165693A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12
PCT/US1992/000556 WO1992013856A1 (en) 1991-02-12 1992-02-03 5-heteroyl indole derivatives

Publications (1)

Publication Number Publication Date
CZ165693A3 true CZ165693A3 (en) 1994-05-18

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
CS931656A CZ165693A3 (en) 1991-02-12 1992-02-03 5-heteroindole derivatives, process of their preparation, intermediates of such process and the use of these compounds

Country Status (24)

Country Link
EP (1) EP0571471B1 (enExample)
JP (1) JPH07121942B2 (enExample)
KR (1) KR930703305A (enExample)
AT (1) ATE135005T1 (enExample)
AU (1) AU655456B2 (enExample)
CA (1) CA2101521A1 (enExample)
CZ (1) CZ165693A3 (enExample)
DE (1) DE69208868T2 (enExample)
DK (1) DK0571471T3 (enExample)
ES (1) ES2084347T3 (enExample)
FI (1) FI933551A0 (enExample)
GR (1) GR3019778T3 (enExample)
HU (1) HUT65766A (enExample)
IE (1) IE920442A1 (enExample)
IL (1) IL100888A0 (enExample)
MX (1) MX9200569A (enExample)
MY (1) MY131298A (enExample)
NO (1) NO932859L (enExample)
NZ (1) NZ241584A (enExample)
PT (1) PT100114A (enExample)
TW (1) TW263508B (enExample)
WO (1) WO1992013856A1 (enExample)
YU (1) YU13792A (enExample)
ZA (1) ZA92969B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (enExample) * 1992-03-05 1996-10-11 Pfizer
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
JP3262800B2 (ja) * 1994-06-01 2002-03-04 ゼネカ・リミテッド 療用複素環化合物
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
CA2234166A1 (en) * 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DE69908330T2 (de) 1998-03-09 2004-02-12 H. Lundbeck A/S 5-heteroaryl-substituierte indole
EP1089993B1 (en) * 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
EP1173432B9 (en) * 1999-04-21 2008-10-15 NPS Allelix Corp. Piperidine-indole compounds having 5-ht6 affinity
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
US7008958B2 (en) 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
ATE401307T1 (de) * 2002-11-28 2008-08-15 Suven Life Sciences Ltd N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
ATE489138T1 (de) 2005-04-13 2010-12-15 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
EP1984351A1 (en) 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
ZA200809659B (en) 2006-04-13 2010-03-31 Neuraxon Inc 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
JP2010500372A (ja) * 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
WO2016179343A1 (en) 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP4423062A4 (en) * 2021-10-29 2025-08-27 Psilera Inc MODIFIED INDOLE COMPOUNDS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
EP0225726B1 (en) * 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
CZ288351B6 (en) * 1990-06-07 2001-05-16 Astrazeneca Ab Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof

Also Published As

Publication number Publication date
FI933551A7 (fi) 1993-08-11
MY131298A (en) 2007-08-30
YU13792A (sh) 1994-11-15
IL100888A0 (en) 1992-11-15
AU655456B2 (en) 1994-12-22
IE920442A1 (en) 1992-08-12
HU9302328D0 (en) 1993-10-28
ATE135005T1 (de) 1996-03-15
FI933551L (fi) 1993-08-11
EP0571471A1 (en) 1993-12-01
AU1263792A (en) 1992-09-07
JPH06500122A (ja) 1994-01-06
DK0571471T3 (da) 1996-04-01
NO932859D0 (no) 1993-08-11
WO1992013856A1 (en) 1992-08-20
JPH07121942B2 (ja) 1995-12-25
EP0571471B1 (en) 1996-03-06
ES2084347T3 (es) 1996-05-01
NZ241584A (en) 1994-12-22
CA2101521A1 (en) 1992-08-13
MX9200569A (es) 1992-08-01
DE69208868D1 (de) 1996-04-11
ZA92969B (en) 1993-08-11
GR3019778T3 (en) 1996-07-31
HUT65766A (en) 1994-07-28
DE69208868T2 (de) 1996-10-17
TW263508B (enExample) 1995-11-21
FI933551A0 (fi) 1993-08-11
NO932859L (no) 1993-08-11
PT100114A (pt) 1993-05-31
KR930703305A (ko) 1993-11-29

Similar Documents

Publication Publication Date Title
EP0571471B1 (en) 5-heteroyl indole derivatives
US5409941A (en) 5-heteroyl indole derivatives
CN1122032C (zh) 用于治疗心血管疾病的新的取代吡唑衍生物
CN1187330C (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CA2169179C (en) 5-arylindole derivatives
AU671836B2 (en) Fused imidazole and triazole derivatives as 5-HT1 receptor agonists
CZ283001B6 (cs) 5-Arylindolové deriváty, meziprodukty pro jejich výrobu a famaceutické prostředky na jejich bázi
EP0773942A1 (en) 4-indole derivatives as serotonin agonists and antagonists
BG60402B2 (bg) Заместени бициклични съединения
JPH01268687A (ja) アザ環状置換基結合の５員環系
JP2010532748A (ja) カルシウムチャネル遮断薬としての２−置換インドール誘導体
SK105294A3 (en) Indole derivatives, method of their preparation, intermediates of this process, pharmaceutical agents containing these derivatives and use of these derivatives
CN102224154A (zh) 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
CS85692A3 (en) 6-HETEROCYCLO-4-AMINO-1,3,4,5-TETRAHYDROBENZO(cd)INDOLE
CA1337202C (en) Cyclic amides which are leukotriene antagonists
EP0227241B1 (en) Medicinal indole and indazole keto sulphone derivatives
US5510359A (en) Heteroaromatic 5-hydroxytryptamine receptor agonists
JPH0378854B2 (enExample)
AU673098B2 (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
US5521188A (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
FR2761070A1 (fr) Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
US5047402A (en) Cyclic amides as medicaments
HK1024243A (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
HK1023119B (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases